# Visnagin Protects Against Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Oxidative Stress and Reducing Ferroptosis

**Authors:** Sheng-Wen Wu, Chen-Yu Chiang, Chien-Ying Lee, Shiuan-Shinn Lee, Wen-Ying Chen, Chun-Jung Chen, Ching-Chi Tseng, Yin-Che Lu, Yu-Hsiang Kuan

PMC · DOI: 10.7150/ijms.125642 · 2026-02-18

## TL;DR

Visnagin protects against kidney damage in sepsis by reducing oxidative stress and ferroptosis in mice and kidney cells.

## Contribution

Visnagin's multitarget therapeutic potential in sepsis-associated acute kidney injury is demonstrated for the first time.

## Key findings

- Visnagin reduced lipid peroxidation and Fe2+ levels in LPS-induced AKI mice.
- Visnagin inhibited p-Akt and p-Nrf2 and scavenged free radicals in HK-2 cells.
- Visnagin modulated oxidative stress and ferroptosis via Akt/Nrf2 and ACSL4/TfR1 pathways.

## Abstract

Sepsis-associated acute kidney injury (SA-AKI) is a life-threatening condition driven by oxidative stress, ferroptosis, and inflammation, yet effective treatments remain unavailable. Visnagin has antioxidant and anti-inflammatory properties and has been traditionally used for cardiovascular and renal disorders, but its role in modulating ferroptosis and redox imbalance in SA-AKI remains unclear. Thus, the study investigated the renoprotective effects of visnagin in a murine lipopolysaccharide (LPS)-induced AKI model, focusing on oxidative stress and ferroptosis.

A systems pharmacology approach integrating network-based target prediction and molecular docking identified candidate targets. In vivo and in vitro validations in LPS-induced AKI mice and HK-2 cells assessed histopathology, oxidative biomarkers, ferroptosis mediators, and key signaling pathways.

Visnagin demonstrated affinity binding to AKT1, NFE2L2, ACSL4, and TFRC, indicating a potential role in modulating oxidative stress and ferroptosis. In vivo, visnagin alleviated renal injury, reduced lipid peroxidation, and downregulated ACSL4 and TfR1 expression, with this accompanied by reduction in renal Fe2+ levels. Although visnagin reduced the protein abundance of SOD, catalase, and GSH-Px, it markedly enhanced their enzymatic activities, likely due to decreased oxidative burden and preservation of enzyme functionality under LPS-induced stress. Additionally, visnagin inhibited p-Akt and p-Nrf2, suggesting suppression of upstream signaling pathways. In vitro, visnagin reduced intracellular ROS levels in HK-2 cells and exhibited scavenging activity against various radical species.

Visnagin exerts protective actions through both modulation of Akt/Nrf2 signaling ACSL4/TfR1 signaling and direct free radical scavenging. These findings underscore visnagin's potential as a multitarget therapeutic agent for SA-AKI.

## Linked entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780], ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182], TFRC (transferrin receptor) [NCBI Gene 7037], SOD1 (superoxide dismutase 1) [NCBI Gene 6647], Gpx1 (glutathione peroxidase 1) [NCBI Gene 24404]
- **Proteins:** Akt (Akt kinase), TFRC (transferrin receptor), Cat (Catalase), Gpx1 (glutathione peroxidase 1)
- **Chemicals:** Visnagin (PubChem CID 6716)
- **Diseases:** Acute kidney injury (MONDO:0002492)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cebpb (CCAAT/enhancer binding protein beta) [NCBI Gene 12608] {aka C/EBPbeta, CRP2, IL-6DBP, LAP, LIP, NF-IL6}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, Prdx6-ps2 (peroxiredoxin 6 pseudogene 2) [NCBI Gene 384001] {aka Aop2-rs2, GPx*, Prdx6-rs2}, Gpx1 (glutathione peroxidase 1) [NCBI Gene 24404] {aka GSHPx, GSHPx-1}, CAT (catalase) [NCBI Gene 847], NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, Trf (transferrin) [NCBI Gene 22041] {aka Cd176, HP, Tf, Tfn, hpx}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, Acsl4 (acyl-CoA synthetase long-chain family member 4) [NCBI Gene 50790] {aka 9430020A05Rik, ACS4, Facl4, Lacs4}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, Keap1 (kelch-like ECH-associated protein 1) [NCBI Gene 50868] {aka INRF2, mKIAA0132}, Hmox1 (heme oxygenase 1) [NCBI Gene 15368] {aka D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32}, Tfrc (transferrin receptor) [NCBI Gene 22042] {aka 2610028K12Rik, CD71, E430033M20Rik, Mtvr1, TFR, TFR1}, Sod2 (superoxide dismutase 2, mitochondrial) [NCBI Gene 20656] {aka MnSOD, Sod-2}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 56637] {aka 7330414F15Rik, 8430431H08Rik, GSK-3, GSK-3beta, GSK3}
- **Diseases:** endotoxemia (MESH:D019446), rhabdomyolysis (MESH:D012206), epileptic seizures (MESH:D004827), deaths (MESH:D003643), cardiovascular and renal disorders (MESH:D002318), myocardial ischemia (MESH:D017202), cytotoxic (MESH:D064420), kidney stones (MESH:D007669), Kidney Disease (MESH:D007674), gram-negative bacterial infections (MESH:D016905), cerebral injury (MESH:D000070625), endothelial (MESH:D005642), cognitive dysfunction (MESH:D003072), Sepsis (MESH:D018805), whooping cough (MESH:D014917), inflammation (MESH:D007249), critically ill (MESH:D016638), iron overload (MESH:D019190), renal fibrosis (MESH:D005355), mitochondrial dysfunction (MESH:D028361), Tubular injury (MESH:D000230), angina pectoris (MESH:D000787), tubular epithelial injury (MESH:D002277), lesions (MESH:D009059), myocardial damage (MESH:D009202), AKI (MESH:D058186), SA (MESH:D013615), ischemia (MESH:D007511), hypotension (MESH:D007022), histopathological damage (MESH:D020263)
- **Chemicals:** Superoxide (MESH:D013481), Dulbecco's eagle medium (-), H2O2 (MESH:D006861), SA (MESH:D000077145), polyunsaturated fatty acids (MESH:D005231), DCF (MESH:D015649), glycerol (MESH:D005990), acyl-CoA (MESH:D000214), dexamethasone (MESH:D003907), MTT (MESH:C070243), heme (MESH:D006418), MDA (MESH:D008315), potassium persulfate (MESH:C009007), isoproterenol (MESH:D007545), glutathione (MESH:D005978), CO2 (MESH:D002245), paraformaldehyde (MESH:C003043), Lipid (MESH:D008055), ABTS (MESH:C002502), LPS (MESH:D008070), NADH (MESH:D009243), PMS (MESH:D011399), Hydrogen (MESH:D006859), polyvinylidene difluoride (MESH:C024865), TBARS (MESH:D017392), DMSO (MESH:D004121), Periodic acid (MESH:D010504), ROS (MESH:D017382), furanochromone (MESH:C477662), paraffin (MESH:D010232), saline (MESH:D012965), methanol (MESH:D000432), MK-2206 (MESH:C548887), formazan (MESH:D005562), xylene (MESH:D014992), carbon monoxide (MESH:D002248), DPPH (MESH:C004931), biliverdin (MESH:D001664), phospholipids (MESH:D010743), arachidonic acid (MESH:D016718), iron (MESH:D007501), DCFH-DA (MESH:C029569), DEX (MESH:D003915), 4-HNE (MESH:C027576), sodium dodecyl sulfate (MESH:D012967), SC- (MESH:D012538), ethanol (MESH:D000431), aldehyde (MESH:D000447), Visnagin (MESH:C044999), hydroxyl radicals (MESH:D017665)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Visnaga daucoides (species) [taxon 1053409], Mus musculus (house mouse, species) [taxon 10090]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965074/full.md

---
Source: https://tomesphere.com/paper/PMC12965074